- Conditions
- Mental Health Wellness 1, Stress, Psychological, Depression, Anxiety
- Interventions
- Heartfulness Meditation
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Transplant Failure and Rejection
- Interventions
- The Prospera™ Test
- Diagnostic Test
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
- Conditions
- Obesity
- Interventions
- Cetrorelix, Gonadorelin-GnRH, Recombinant LH, Letrozole
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Kidney Transplantation
- Interventions
- Tofacitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more
- Conditions
- Cardiovascular Disease, Acute Coronary Syndrome
- Interventions
- Multifaceted Intervention with pharmacist and IVR
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 91 Years
- Enrollment
- 14,573 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 15
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 12 more
- Conditions
- Prader-Willi Syndrome
- Interventions
- DCCR, Placebo for DCCR
- Drug
- Lead sponsor
- Soleno Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 20
- States / cities
- Orange, California • Palo Alto, California • San Diego, California + 17 more
- Conditions
- Cow's Milk Allergy
- Interventions
- Experimental Extensively Hydrolyzed Formula, Placebo Extensively Hydrolyzed Formula
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Chapel Hill, North Carolina + 1 more
- Conditions
- Plaque Psoriasis
- Interventions
- NIS
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 34 more
- Conditions
- Hemorrhage
- Interventions
- No treatment
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Urothelial Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Orange, California • Palo Alto, California + 8 more
- Conditions
- Carcinoma, Transitional Cell
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 809 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 41
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 29 more
- Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Edecesertib, Edecesertib Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Fremont, California • Aurora, Colorado + 9 more
- Conditions
- Relapsed/Refractory Ovarian Carcinoma
- Interventions
- NTB-928
- Drug
- Lead sponsor
- TeneoSeven, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- MM-121, Erlotinib
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 16 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- bevacizumab, sorafenib tosylate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 204
- States / cities
- Scottsdale, Arizona • Fresno, California • Fort Collins, Colorado + 129 more
- Conditions
- Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, Advanced Solid Tumor, Metastatic Solid Tumor, ALK Gene Mutation
- Interventions
- TPX-0131
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Orange, California • Aurora, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- High dose testosterone
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more
- Conditions
- Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances
- Interventions
- Personalized modifications to treatment to address menstrual cycle effects on glycemia
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Tarceva, carboplatin, paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 38
- States / cities
- Alhambra, California • Bakersfield, California • Concord, California + 31 more
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- Mizagliflozin 5 mg, Mizagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Vogenx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- Chula Vista, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Hemophilia A
- Interventions
- Not listed
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2040
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Rectal Cancer
- Interventions
- Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin, Capecitabine (Xeloda®), intensity modulated radiotherapy (IMRT), Quality of Life Questionnaires, DRE-Endoscopy
- Drug · Radiation · Behavioral + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 26
- States / cities
- Irvine, California • Orange, California • San Francisco, California + 22 more
- Conditions
- Lupus Nephritis
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 17
- States / cities
- Glendale, Arizona • Phoenix, Arizona • La Jolla, California + 13 more